We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

19 hedge funds and large institutions have $7.91M invested in Evoke Pharma in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.01% less ownership

Funds ownership: 0.13% → 0.13% (-0.01%)

10% less funds holding

Funds holding: 21 → 19 (-2)

18% less capital invested

Capital invested by funds: $9.64M → $7.91M (-$1.73M)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
19
Holders Change
-2
Holders Change %
-9.52%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
+$49.2K
2
BFM
Boothbay Fund Management
New York
+$30K
3
BlackRock
BlackRock
New York
+$11.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.88K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$111K
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$82K
3
VF
Virtu Financial
New York
-$80K
4
TSS
Two Sigma Securities
New York
-$55K
5
UBS Group
UBS Group
Switzerland
-$9.62K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
1
Sphera Funds Management
Israel
$3.5M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.34M +$8.88K +24 +0.6%
SOMRS
3
State of Michigan Retirement System
Michigan
$992K – – –
KCM
4
Knoll Capital Management
Florida
$682K – – –
6CM
5
683 Capital Management
New York
$283K – – –
Creative Planning
6
Creative Planning
Kansas
$248K – – –
BlackRock
7
BlackRock
New York
$207K +$11.1K +30 +5%
BFM
8
Boothbay Fund Management
New York
$129K +$30K +81 +29%
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$91K – – –
Northern Trust
10
Northern Trust
Illinois
$84K – – –
WA
11
Wambolt & Associates
Colorado
$82K +$85.1K +230 New
Commonwealth Equity Services
12
Commonwealth Equity Services
Massachusetts
$80K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$57K – – –
SIM
14
Spark Investment Management
New York
$47K +$49.2K +133 New
Morgan Stanley
15
Morgan Stanley
New York
$39K -$370 -1 -0.9%
UCFA
16
United Capital Financial Advisors
Texas
$39K – – –
UBS Group
17
UBS Group
Switzerland
$8K -$9.62K -26 -54%
LC
18
Lindbrook Capital
California
$2K +$2.59K +7 New
Citigroup
19
Citigroup
New York
$1K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
– -$111K -259 Closed
PNC Financial Services Group
21
PNC Financial Services Group
Pennsylvania
– -$82K -191 Closed
VF
22
Virtu Financial
New York
– -$80K -185 Closed
TSS
23
Two Sigma Securities
New York
– -$55K -129 Closed
Bank of America
24
Bank of America
North Carolina
– -$8K -20 Closed

EVOK Hedge Fund Activity: Q4 2018 in Review

19 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2018, worth a combined $7.91M — down 18% from $9.64M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EVOK and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Spark Investment Management, opening a new position worth an estimated $49.2K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $111K sold.

  • 19 institutional investors held Evoke Pharma (EVOK) as of Q4 2018, down from 21 in Q3 2018.
  • Funds reported $7.91M of Evoke Pharma stock for Q4 2018, down 18% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q4 2018 and 5 closed out, a net change of -2 holders.
  • The largest Evoke Pharma buyer in Q4 2018 was Spark Investment Management, an estimated $49.2K added.
  • The largest Evoke Pharma seller in Q4 2018 was JP Morgan Chase, an estimated $111K sold.

Based on aggregated 13F filings for Q4 2018.